In 2005, Theregen received FDA approval to proceed with a phase I safety trial for patients suffering from this cardiovascular disorder. The product will serve as an adjunct therapy to revascularization procedures that include coronary artery bypass graft surgery. The company intends to initiate its Anginera phase I safety trial in this quarter.
“We believe our Anginera therapy has the potential to benefit patients suffering from a variety of chronic, debilitating cardiovascular diseases,” said Theregen CEO Thomas Schreck. “We are very pleased to announce this strategic investment for Theregen, not only due to the capital it affords to advance our clinical program, but also for the access to highly regarded professionals within Guidant.”